Ovid Therapeutics (OVID) Shares Outstanding (2016 - 2026)
Ovid Therapeutics' (OVID) quarterly Shares Outstanding (Entity) came in at $136.2 million in Q1 2026, up 91.5% YoY from $71.1 million in Q1 2025, and up 84.68% on a QoQ basis from $73.7 million in Q4 2025.
Ovid Therapeutics (OVID) Shares Outstanding (2016 - 2026) Analysis & Trends
Ovid Therapeutics (OVID) has 11 years of Shares Outstanding (Entity) data on file, last reported at $136.2 million in Q1 2026.
- Quarterly Shares Outstanding (Entity) rose 91.5% year-over-year to $136.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $136.2 million (up 91.5% YoY) and the FY2025 annual result came in at $73.7 million, up 3.84% from the prior year.
- Shares Outstanding (Entity) grew to $136.2 million in Q1 2026, from $73.7 million in the prior quarter.
- In the past five years, Shares Outstanding (Entity) ranged from a high of $136.2 million in Q1 2026 to a low of $70.4 million in Q1 2022.
- A 5-year average of $74.8 million and a median of $70.8 million in 2024 frame the typical range for Shares Outstanding (Entity).
- Annual changes were most pronounced in 2023 — Shares Outstanding (Entity) advanced 0.11% — and 2026, when it soared 91.5%.
- Tracing OVID's Shares Outstanding (Entity) over 5 years: stood at $70.5 million in 2022, then rose by 0.32% to $70.7 million in 2023, then climbed by 0.45% to $71.0 million in 2024, then gained by 3.84% to $73.7 million in 2025, then soared by 84.68% to $136.2 million in 2026.
- The last three Shares Outstanding (Entity) figures came in at $136.2 million (Q1 2026), $73.7 million (Q4 2025), and $71.2 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 253.70 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 102.80 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 62.19 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 210.89 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.45 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 25.05 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 445.06 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 133.61 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 217.35 Mn |
| 10 | Ovid Therapeutics | 385.37 Mn | 229.84 Mn | - | 136.17 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 136.17 Mn |
| Dec 31, 2025 | 73.74 Mn |
| Sep 30, 2025 | 71.11 Mn |
| Jun 30, 2025 | 71.11 Mn |
| Mar 31, 2025 | 71.05 Mn |
| Dec 31, 2024 | 70.91 Mn |
| Sep 30, 2024 | 70.98 Mn |
| Jun 30, 2024 | 70.92 Mn |
| Mar 31, 2024 | 70.72 Mn |
| Dec 31, 2023 | 70.58 Mn |
| Sep 30, 2023 | 70.62 Mn |
| Jun 30, 2023 | 70.53 Mn |
| Mar 31, 2023 | 70.49 Mn |
| Dec 31, 2022 | 70.42 Mn |
| Sep 30, 2022 | 70.43 Mn |
| Jun 30, 2022 | 70.39 Mn |
| Mar 31, 2022 | 70.35 Mn |
| Dec 31, 2021 | 67.48 Mn |
| Sep 30, 2021 | 67.93 Mn |
| Jun 30, 2021 | 67.82 Mn |